Search - tctmd.com

Displaying 81 - 100 of 516

Sort: Relevancy | Date

News Conference News ACC 2023

Short DAPT Noninferior to 1 Year After Ultrathin DES PCI: HOST-IDEA

Yael L. Maxwell

March 09, 2023

News Daily News

P2Y12 Monotherapy Better Than Continued DAPT Even After Complex PCI

Yael L. Maxwell

February 06, 2023

News Daily News

Brachytherapy Remains an Option for DES In-Stent Restenosis

Yael L. Maxwell

January 12, 2023

News Daily News

Routine Coronary Tests Prior to Kidney Transplant Questioned

Yael L. Maxwell

January 05, 2023

News Opinion CV Team Dispatch

December 2022 News Roundup

L.A. McKeown

December 28, 2022

News Daily News

Nuisance Bleeds on DAPT Not Just an Annoyance: TALOS-AMI Analysis

Caitlin E. Cox

November 30, 2022

News Daily News

P2Y12 Inhibitors Top Aspirin Following Post-PCI DAPT: Network Meta-analysis

Todd Neale

November 21, 2022

News Daily News

Single-Center Study Offers Insights for Ticagrelor vs Prasugrel in Chronic CAD

Yael L. Maxwell

November 21, 2022

News Conference News AHA 2022

RESPECT-EPA: Missed Primary Endpoint but Hints of Benefit With Icosapent Ethyl

Todd Neale

November 10, 2022

News Conference News AHA 2022

Another OPTION? Indobufen Noninferior to Aspirin Following Successful PCI

Yael L. Maxwell

November 10, 2022

News Conference News AHA 2022

ISCHEMIA-EXTEND: So Far, Deaths Match for Invasive and Conservative Arms in Stable CAD

Shelley Wood

November 06, 2022

News Daily News

New Biomarker-Based Risk Score Performs Well in ACS

Michael O'Riordan

October 25, 2022

News Conference News TCT 2022

RIVARAD: Rivaroxaban a Possible Solution to Radial Artery Occlusion

Todd Neale

September 21, 2022

Presentation TCT 2022

TCT 151: Dual Antiplatelet Therapy after Percutaneous Coronary Intervention for Left Main Coronary Artery Disease

Presenter: Sungsoo Cho

September 18, 2022

Presentation TCT 2022

TCT 328: Low-dose or Standard-dose Edoxaban versus Dual Antiplatelet Therapy for Leaflet Thrombus and Cerebral Thromboembolism after Transcatheter Aortic Valve Replacement (TAVR): Subgroup Analysis of the Randomized ADAPT-TAVR Trial

Presenter: Mijin Kim

September 18, 2022

Presentation TCT 2022

TCT 4: Dual Antiplatelet Therapy for 1 Versus 3 Months in Women and Men at High Bleeding Risk Undergoing Drug-Eluting Stent Implantation

Presenter: Johny Nicolas

September 17, 2022

Presentation TCT 2022

TCT 2: Two-Year Outcomes in High Bleeding Risk Patients with Bifurcations after Percutaneous Coronary Intervention and One Month Dual Antiplatelet Therapy

Presenter: Ajay Kirtane

September 17, 2022

Presentation TCT 2022

TCT 15: Dual antiplatelet therapy-based de-escalation in acute coronary syndrome: An individual patient data meta-analysis

Presenter: Jeehoon Kang

September 17, 2022

Presentation TCT 2022

TCT 59: Impact of prolonged dual antiplatelet therapy duration on bioresorbable scaffolds outcomes: five-year data from a prospective registry.

Presenter: Giulia Masiero

September 17, 2022

Presentation TCT 2022

TCT 21: Preferred Strategy in the Era of Short-Term Dual Antiplatelet Therapy: A Systematic Review and Network Meta-Analysis of Randomized Trials

Presenter: Toshiki Kuno

September 17, 2022

Advertisement

Short DAPT Noninferior to 1 Year After Ultrathin DES PCI: HOST-IDEA

P2Y12 Monotherapy Better Than Continued DAPT Even After Complex PCI

Brachytherapy Remains an Option for DES In-Stent Restenosis

Routine Coronary Tests Prior to Kidney Transplant Questioned

December 2022 News Roundup

Nuisance Bleeds on DAPT Not Just an Annoyance: TALOS-AMI Analysis

P2Y12 Inhibitors Top Aspirin Following Post-PCI DAPT: Network Meta-analysis

Single-Center Study Offers Insights for Ticagrelor vs Prasugrel in Chronic CAD

RESPECT-EPA: Missed Primary Endpoint but Hints of Benefit With Icosapent Ethyl

Another OPTION? Indobufen Noninferior to Aspirin Following Successful PCI

ISCHEMIA-EXTEND: So Far, Deaths Match for Invasive and Conservative Arms in Stable CAD

New Biomarker-Based Risk Score Performs Well in ACS

RIVARAD: Rivaroxaban a Possible Solution to Radial Artery Occlusion

TCT 151: Dual Antiplatelet Therapy after Percutaneous Coronary Intervention for Left Main Coronary Artery Disease

TCT 328: Low-dose or Standard-dose Edoxaban versus Dual Antiplatelet Therapy for Leaflet Thrombus and Cerebral Thromboembolism after Transcatheter Aortic Valve Replacement (TAVR): Subgroup Analysis of the Randomized ADAPT-TAVR Trial

TCT 4: Dual Antiplatelet Therapy for 1 Versus 3 Months in Women and Men at High Bleeding Risk Undergoing Drug-Eluting Stent Implantation

TCT 2: Two-Year Outcomes in High Bleeding Risk Patients with Bifurcations after Percutaneous Coronary Intervention and One Month Dual Antiplatelet Therapy

TCT 15: Dual antiplatelet therapy-based de-escalation in acute coronary syndrome: An individual patient data meta-analysis

TCT 59: Impact of prolonged dual antiplatelet therapy duration on bioresorbable scaffolds outcomes: five-year data from a prospective registry.

TCT 21: Preferred Strategy in the Era of Short-Term Dual Antiplatelet Therapy: A Systematic Review and Network Meta-Analysis of Randomized Trials

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content